Hillhurst Bio Doses First Subject in Phase 2a Clinical Trial of HBI-002, a Novel Therapy for Parkinson's Disease
Hillhurst Biopharmaceuticals has initiated a Phase 2a clinical trial for HBI-002, a novel oral drug aimed at treating Parkinson's disease. The study, funded by The Michael J. Fox Foundation, investigates the neuroprotective potential of a therapy based on epidemiological data regarding smokers.
Why it matters
This trial represents a potential breakthrough in addressing the underlying biology of Parkinson's disease, a major unmet medical need.
SAN DIEGO , June 15, 2026 /PRNewswire/ -- Hillhurst Biopharmaceuticals Inc. ("Hillhurst Bio"), a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products based on known inhaled therapeutics, today announced that the first subject has been dosed in its Phase 2a clinical trial evaluating HBI-002 for the treatment of Parkinson's disease. This trial is supported by funding from The Michael J. Fox Foundation for Parkinson's Research (MJFF), as part of its Therapeutics Pipeline Program, and the Farmer Family Foundation.
The article is a standard corporate press release reporting on clinical trial milestones.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in